Online inquiry

IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13849MR)

This product GTTS-WQ13849MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13849MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3964MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ11610MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ14483MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ1583MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ15981MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ9844MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ5790MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ5880MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW